InjectiMed Competitors

As healthcare needs and demands are increasing every day, the challenges increase as well. The healthcare industry accepts these challenges and invents solutions daily. Among the healthcare providers, Ameesa is well known as one of the most reliable sources in the region for medical products for diagnostic and therapeutic Interventional Cardiovascular lines. We've been proud to be a part of this industry for over 30 years. We aim to provide the world's best medical technologies in clinics and hospitals. Since we launched in 1985 we've been glad to be business partners with AVE, USCI, BARD, NuMed, Microvena, Merit Medical, Medtronic, Bentley InnoMed, Angioscore, Spectranetics, Perouse Medical, Elixir Medical, and Meril Life Science over the years.

NEVA, New England Vascular Access, provides expert, innovative and cutting edge vascular access device placement. Midline and peripherally inserted central catheters are the primary devices used for short and long-term infusions. For renal patients, we offer internal jugular access. What sets NEVA apart is our skill set and commitment to the highest standard of care. With many options for access, facilities can be confident their patients will receive the right device at the right time ensuring the lowest complication rates. Timely insertion of vascular devices in difficult intravenous access patients decreases delays in treatment and expedites discharge. In long term care, obtaining vascular access means preventing an unwanted and often unnecessary hospitalization. Keeping your resident in your facility is our top priority.

As a leading medical device company, we specialize in developing innovative vascular closure solutions, a critical aspect of catheter-based cardiovascular procedures. Our unwavering focus on vascular closure has enabled us to understand the needs of patients, physicians, and providers during and after these procedures, allowing us to create a highly focused sales force. Our groundbreaking SITESEAL™ and SITESEAL SV™ devices employ a non-variant pressure system and leverage the natural clot-inducing properties of optimal pressure, offering a transformative solution for vascular closure. Our products reduce complication rates and improve hospital workflow, providing a unique value proposition for our customers with considerable economic benefits. We plan to expand our presence in high-volume healthcare centers across the U.S. and capture a significant share of the $1.4 billion annual U.S. market for vascular access site closure in catheter-based, coronary, peripheral, and electrophysiology procedures. Our SITESEAL™ family of products addresses the limitations of manual compression and existing vascular closure devices by delivering increased workflow efficiency, reduced access site complications, enhanced patient comfort, and cost savings. Our devices cater to hospitals, ambulatory surgery, and EP procedure centers. We are well-positioned to compete in the market with an innovative approach, attractive economic value proposition, efficient commercial model, scalable manufacturing capabilities, and a sole focus on vascular closure. Our revenue is generated from the sales of our SITESEAL™ and SITESEAL SV™ devices. We plan to continue expanding our sales force to penetrate further into existing customer accounts while targeting high-volume healthcare centers across the US. Join us on our journey to revolutionize vascular closure, deliver advanced patient care, and streamline cardiovascular procedures for hospitals and treatment facilities worldwide.